- Home
- RARE vs TGS Comparison
RARE vs TGS Comparison
Compare RARE & TGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- TGS
- Stock Information
- Founded
- RARE 2010
- TGS 1992
- Country
- RARE United States
- TGS Argentina
- Employees
- RARE N/A
- TGS N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- TGS Natural Gas Distribution
- Sector
- RARE Health Care
- TGS Utilities
- Exchange
- RARE Nasdaq
- TGS Nasdaq
- Market Cap
- RARE 3.6B
- TGS 4.1B
- IPO Year
- RARE 2014
- TGS N/A
- Fundamental
- Price
- RARE $33.84
- TGS $27.18
- Analyst Decision
- RARE Strong Buy
- TGS Strong Buy
- Analyst Count
- RARE 15
- TGS 1
- Target Price
- RARE $95.93
- TGS $35.00
- AVG Volume (30 Days)
- RARE 748.6K
- TGS 256.8K
- Earning Date
- RARE 05-01-2025
- TGS 05-05-2025
- Dividend Yield
- RARE N/A
- TGS N/A
- EPS Growth
- RARE N/A
- TGS 622.80
- EPS
- RARE N/A
- TGS 0.48
- Revenue
- RARE $560,230,000.00
- TGS $1,183,090,354.00
- Revenue This Year
- RARE $19.15
- TGS N/A
- Revenue Next Year
- RARE $32.11
- TGS N/A
- P/E Ratio
- RARE N/A
- TGS $13.58
- Revenue Growth
- RARE 29.01
- TGS 23.70
- 52 Week Low
- RARE $33.69
- TGS $14.16
- 52 Week High
- RARE $60.37
- TGS $34.37
- Technical
- Relative Strength Index (RSI)
- RARE 27.75
- TGS 51.42
- Support Level
- RARE $36.71
- TGS $25.90
- Resistance Level
- RARE $39.21
- TGS $29.30
- Average True Range (ATR)
- RARE 1.34
- TGS 1.45
- MACD
- RARE -0.32
- TGS 0.11
- Stochastic Oscillator
- RARE 2.19
- TGS 50.35
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About TGS Transportadora de Gas del Sur SA TGS
Transportadora de Gas del Sur SA is a transporters of natural gas in Latin America. The company's operating segments include Natural Gas Transportation, Midstream, Telecommunications, and Production and Commercialization Liquids, Other Services, and Telecommunications. It generates maximum revenue from the Production and Commercialization of the Liquids segment. Geographically, it derives the majority of its revenue from Argentina.